CDK9 and anaplastic astrocytoma: Zotiraciclib is an orally-available CDK9 inhibitor with established CNS penetrance in several preclinical models94–96 and an acceptable safety profile in phase I/II trials for adults with anaplastic astrocytoma or glioblastoma97 (NCT03224104, NCT02942264).